Stockscreener 앱 받기
33.91
0.24%
0.08
시간 외 거래:
33.90
-0.010
-0.03%
전일 마감가:
$33.83
열려 있는:
$33.8
하루 거래량:
711.63K
Relative Volume:
1.79
시가총액:
$1.63B
수익:
-
순이익/손실:
$-107.28M
주가수익비율:
-13.03
EPS:
-2.6031
순현금흐름:
$-80.71M
1주 성능:
-16.17%
1개월 성능:
-33.73%
6개월 성능:
+17.42%
1년 성능:
+35.80%
1일 변동 폭
$33.05
$34.89
1주일 범위
$31.58
$42.18
52주 변동 폭
$23.75
$52.93
Rapport Therapeutics Inc Stock (RAPP) Company Profile
명칭
Rapport Therapeutics Inc
전화
857-321-8020
주소
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
33.91 | 1.63B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-02 | 개시 | Wells Fargo | Overweight |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-16 | 개시 | Truist | Buy |
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-04-08 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 개시 | Jefferies | Buy |
| 2024-07-02 | 개시 | Stifel | Buy |
| 2024-07-02 | 개시 | TD Cowen | Buy |
모두보기
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Show Me The Money: Rapport Stock Up Over 400% In 16 Months; Bipolar Mania Data Next - rttnews.com
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com Nigeria
Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com India
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com
Rapport Therapeutics shares drop 18% on updates for RAP-219 and upcoming bipolar mania trial data - Pluang
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med (NASDAQ:RAPP) - Seeking Alpha
Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR) - The Globe and Mail
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why is Rapport Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Rapport Therapeutics at TD Cowen summit: bipolar data loom By Investing.com - Investing.com Canada
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success - Seeking Alpha
Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potential - Investing.com Canada
Raymond James reiterates Strong Buy on Rapport Therapeutics stock - Investing.com
RAPP: RAP-219 targets TARPγ8 for bipolar mania, aiming to address major unmet needs with a novel approach - TradingView
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Clinical-Stage Biotech with a 49.90% Upside Potential - DirectorsTalk Interviews
RAPPORT THERAPEUTICS, INC. : BTIG RAISES TARGET PRICE TO $75 FROM $65 - webull.com
Why Rapport Therapeutics’ Hot Rally Is Cooling - TipRanks
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $50 to $75 - Moomoo
Rapport Therapeutics Is Maintained at Buy by BTIG - Moomoo
Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
BTIG maintains Buy rating on Rapport Therapeutics, $75 price target - TradingView
(RAPP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Truist reiterates Buy on Rapport Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Truist reiterates Buy on Rapport Therapeutics stock ahead of data - Investing.com
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Australia
Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common shares - Bitget
Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock - investing.com
Rapport Therapeutics Slides As Rally Loses Steam - TipRanks
Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - moomoo.com
Rapport Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Rapport Therapeutics (RAPP) Slips 4% as Biotech Pullback Tests Key SupportRisk Reversal - dars.gov.et
Rapport Therapeutics CEO Abraham Ceesay Sells 18,921 Shares Under Rule 10b5-1 Plan - Kalkine Media
Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades - stocktitan.net
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program - Barchart.com
Rapport Therapeutics' RAP-219 shows promise wit... - Pluang
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise - Seeking Alpha
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 404 Shares - MarketBeat
Rapport Therapeutics CDO Sells 404 Shares Under Rule 10b5-1 Trading Plan - Kalkine Media
Does Widening Losses And Higher EPS Drag Change The Bull Case For Rapport Therapeutics (RAPP)? - simplywall.st
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month HighShould You Buy? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Given "Buy" Rating at BTIG Research - MarketBeat
Trv Gp Vi LLC Takes Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Trv Gp V LLC Takes $261.71 Billion Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Rapport Therapeutics (NASDAQ: RAPP) plans insider sale of 2,092 shares - Stock Titan
Rapport Therapeutics Inc (RAPP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):